1. Home
  2. Labeler Index
  3. Remedyrepack Inc.
  4. 70518-2003
  5. Product Images: Divalproex Sodium

Product Images Divalproex Sodium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Divalproex Sodium NDC 70518-2003 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

MM2 - Divalproex Sodium 500mg 70518 2003 01

MM2 - Divalproex Sodium 500mg 70518 2003 01

Divalproex Sodium is an extended-release tablet containing 500 mg. This prescription medication is packaged in a lot of 100 HD2 tablets, has an NDC number of 70518-2003-01, and it is manufactured by Aurcbindo, Nagar, India 505302. The medication should be kept out of reach of children and stored within the specified temperature range. The package insert provides instructions for use, and it was repackaged by RemedyRepack Inc., Indiana, PA 15701.*

MM3 - Divalproex Sodium 500mg 70518 2003 02

MM3 - Divalproex Sodium 500mg 70518 2003 02

Divalproex Sodium is a Rx-only drug in the form of an extended-release tablet. Each tablet contains 500mg of the active ingredient. The manufacturer is Aurcbindo of Nagar, India. It is important to keep this medication out of the reach of children. Directions for use can be found in the package insert. The drug should be stored between 20-26°C (63-77°F) with excursions permitted to 15-30°C (59-86°F) as per USP guidelines. The medication has been repackaged by RemedyRepack Inc., Indiana, PA 15701.*

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

This is a description of a medication called Divalproex Sodium. It is an extended-release tablet with a strength of 500 mg. The package contains 30 tablets with the label "QTY: 30 HD2". The medication is prescription-only, and the NDC number is 70518-2003-00. The package insert should be consulted for directions for use. The medication should be kept out of children's reach and stored between 20-26°C (63-77°F); excursions permitted to 15-30°C (59-86°F) [See USP]. The medication has been repackaged by RemedyRepack Inc. in Indiana, PA 15701.*

Figure 1 - divalproex fig1

Figure 1 - divalproex fig1

This is a figure showing the percentage of patients who experienced improvement, no change, or worsening in CPS (presumably referring to a medical condition or symptom). The figure compares the results between patients taking Divalproex Sodium Delayed-Release Tablets and those taking a placebo. The title of the figure is "% Reduction in CPS Rate." No additional information is available.*

Figure 2 - divalproex fig2

Figure 2 - divalproex fig2

The text appears to be a graph or chart showing the percentage reduction in CPS rate for patients taking a high and low dose of delayed-release tablets of Divalproex Sodium. It indicates the percentage of patients who experienced improvement, no change, or worsening of their condition.*

figure-3 - divalproex fig3

figure-3 - divalproex fig3

This is a list of numerical data and pharmaceutical product names. There is not enough context to provide a useful description.*

Structure - divalproex str

Structure - divalproex str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.